Home Cart Sign in  
Chemical Structure| 7073-69-0 Chemical Structure| 7073-69-0

Structure of 7073-69-0

Chemical Structure| 7073-69-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 7073-69-0 ]

CAS No. :7073-69-0
Formula : C9H11BrO
M.W : 215.09
SMILES Code : CC(C)(O)C1=C(Br)C=CC=C1
MDL No. :MFCD00767180
Boiling Point : No data available
InChI Key :TXQKNSQVEWHJAQ-UHFFFAOYSA-N
Pubchem ID :329527

Safety of [ 7073-69-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 7073-69-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.33
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 49.77
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

20.23 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.37
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.32
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.57
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.91
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.69
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.57

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.97
Solubility 0.229 mg/ml ; 0.00106 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.38
Solubility 0.889 mg/ml ; 0.00414 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.5
Solubility 0.0674 mg/ml ; 0.000313 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.96 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.27

Application In Synthesis of [ 7073-69-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 7073-69-0 ]

[ 7073-69-0 ] Synthesis Path-Downstream   1~4

  • 2
  • [ 7073-69-0 ]
  • [ 149968-10-5 ]
  • trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
82% A flask under nitrogen was charged with vinyl alcohol IV (97 g), bromo alcohol IIA (81g ), DMF (380 mL) and N,N-dicyclohexylmethylamine (Cy2NMe, 96.5 mL). To the reaction mixture was charged tri-o-tolylphosphine ((o-tol)3P, 506 mg) and trans-diaminedibromopalladium(II) ((NH3)2PdBr2> 454 mg). The batch was heated to 100 C and aged until completion. To the batch was charged 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 68.3 mL). The mixture was heated to 120C and aged for at least 6h. The batch was cooled to 45C, aq. Glycolic acid (56.8 mL, 70 wt %,) was slowly charged. Oxoalcohol VA was crystallized by slow addition of anti-solvent DI water at 55C. The crystalline product was dried at room temperature under vacuum with nitrogen sweep to yield oxoalcohol VA (110.7 g, 82% corrected yield from the vinyl alcohol IV. 1NMR (500MHz, CDCl3) delta 8.25 (m, 1H), 8.11 (d, J= 8.5 Hz, 1H), 8.08 (d, J= 1.5 Hz, 1H), 7.94 (m, 1H), 7.80 (m, 1H), 7.75 (d, J- 17.5 Hz, 1H), 7.72 (d, J= 5.0 Hz, 1H), 7.62 (d, J= 8.5 Hz, 1H), 7.49 (m, 1H), 7.46 (dd, J= 8.6, 2.0 Hz 1H), 7.43 (om, 1H), 7.42 (d, J= 16.3 Hz, 1H), 7.29 (dd, J= 7.6, 1.7 Hz, 1H), 7.24 (m, 1H), 7.19 (m, 1H), 3.49-3.42 (om, 4H), 2.47 (s, 1H), 1.73 (s, 6H). 13C NMR (125MHz, CDCl3) delta 199.7, 156.4, 148.6, 145.6, 139.8, 137.4, 136.8, 136.2, 135.6, 134.0, 131.6, 131.5, 129.6, 129.1, 128.7, 128.24, 128.21, 127.28, 127.26, 126.8, 126.0, 125.75, 125.69, 119.8, 73.8, 42.0, 32.2, 28.5. LC-MS (ESI+) m/z calculated C29H27C1N02 for 456.2 found 456.5 (M+H).
With tetrabutylammomium bromide; sodium acetate;palladium diacetate; In 1-methyl-pyrrolidin-2-one; toluene; at 120℃;Inert atmosphere; 0.8 g (0.0037 mol) of palladium(II) acetate, 20.5 g (0.25 mol) of sodium acetate, 64.5 g (0.20 mol) of tetrabutylammonium bromide were placed under an argon atmosphere and 23.7 g (0.1 1 mol) of bromo-carbinol (III, X=Br) dissolved in 170 cm3 of toluene was added. The mixture was heated to 120C and then 32.2 g (0.10 mol) of chloroquinaldine-alcohol (II) dissolved in 70 cm3 of N-methyl-2-pirrolidone (NMP) was added. The mixture was stirred at 120 C until the reaction was complete. 100 cm3 of saturated NaHC03 solution, 100 cm3 of distilled water and 200 cm3 of ethyl acetate were then added. The mixture was stirred for 5 minutes. The layers were separated. The organic phase was washed three times with 200 cm3 of distilled water and with 200 cm3 of brine. The organic solution was dried over 30 g of sodium sulfate. The drying agent was filtered, washed with 200 cm3 of ethyl acetate and the filtrate was evaporated in vacuum. Yield: 54.7 g crude 1-{3-[(E)-2-(7-Chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(l-hydroxy-l- methyl-ethyl)-phenyl]-propan-l-one (IV) as a brown oil. A small amount of the product was purified by chromatography; the structure was checked by NMR spectroscopy: 1H NMR (DMSO-i/6) delta 1.57 (s, 6H, Me2C), 3.26-3.35 (m, 2H, CH2Ar), 3.40-3.48 (m, 2H, CH2CO), 5.04 (s, 1H, OH), 7.11-7.22 (m, 2H), 7.27-7.32 (m, 1H), 7.36-7.42 (m, 1H), 7.55-7.64 (m, 3H), 7.89-8.04 (m, 6H), 8.32-8.36 (m, 1H), 8.41 (d, 1H, J= 8.6 Hz) ppm.13C NMR (DMSO-i¾ delta 28.5 (CH2Ar), 2 31.8 ( e2C), 41.7 ( H2CO), 72.0 (Me2Q, 120.3, 125.5, 125.5, 125.6, 126.5, 126.8, 127.0, 127.2, 128.0, 129.3, 129.4, 129.7, 131.4, 131.5, 134.1, 134.4, 136.6, 136.6, 137.3, 139.8, 146.8, 148.0, 156.6, 199.6 (CO) ppm.
  • 3
  • [ 7073-69-0 ]
  • [ 149968-10-5 ]
  • trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one [ No CAS ]
  • C29H26ClNO2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With trans dibromo diammine palladium (II); N-Methyldicyclohexylamine; tris-(o-tolyl)phosphine; In N,N-dimethyl-formamide; at 100℃;Inert atmosphere; A flask under nitrogen was charged with vinyl alcohol IV (97 g), bromo alcohol IIA (81g ), DMF (380 mL) and N,N-dicyclohexylmethylamine (Cy2NMe, 96.5 mL). To the reaction mixture was charged tri-o-tolylphosphine ((o-tol)3P, 506 mg) and trans-diaminedibromopalladium(II) ((NH3)2PdBr2> 454 mg). The batch was heated to 100 C and aged until completion. To the batch was charged 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 68.3 mL). The mixture was heated to 120C and aged for at least 6h. The batch was cooled to 45C, aq. Glycolic acid (56.8 mL, 70 wt %,) was slowly charged. Oxoalcohol VA was crystallized by slow addition of anti-solvent DI water at 55C. The crystalline product was dried at room temperature under vacuum with nitrogen sweep to yield oxoalcohol VA (110.7 g, 82% corrected yield from the vinyl alcohol IV. 1NMR (500MHz, CDCl3) delta 8.25 (m, 1H), 8.11 (d, J= 8.5 Hz, 1H), 8.08 (d, J= 1.5 Hz, 1H), 7.94 (m, 1H), 7.80 (m, 1H), 7.75 (d, J- 17.5 Hz, 1H), 7.72 (d, J= 5.0 Hz, 1H), 7.62 (d, J= 8.5 Hz, 1H), 7.49 (m, 1H), 7.46 (dd, J= 8.6, 2.0 Hz 1H), 7.43 (om, 1H), 7.42 (d, J= 16.3 Hz, 1H), 7.29 (dd, J= 7.6, 1.7 Hz, 1H), 7.24 (m, 1H), 7.19 (m, 1H), 3.49-3.42 (om, 4H), 2.47 (s, 1H), 1.73 (s, 6H). 13C NMR (125MHz, CDCl3) delta 199.7, 156.4, 148.6, 145.6, 139.8, 137.4, 136.8, 136.2, 135.6, 134.0, 131.6, 131.5, 129.6, 129.1, 128.7, 128.24, 128.21, 127.28, 127.26, 126.8, 126.0, 125.75, 125.69, 119.8, 73.8, 42.0, 32.2, 28.5. LC-MS (ESI+) m/z calculated C29H27C1N02 for 456.2 found 456.5 (M+H).
  • 4
  • [ 7073-69-0 ]
  • [ 149968-10-5 ]
  • [ 287930-77-2 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 7073-69-0 ]

Aryls

Chemical Structure| 30951-66-7

A185319 [30951-66-7]

2-(3-Bromophenyl)propan-2-ol

Similarity: 0.98

Chemical Structure| 2077-19-2

A512869 [2077-19-2]

2-(4-Bromophenyl)propan-2-ol

Similarity: 0.95

Chemical Structure| 134615-22-8

A265000 [134615-22-8]

(S)-1-(3-Bromophenyl)ethanol

Similarity: 0.93

Chemical Structure| 109240-30-4

A505333 [109240-30-4]

1-(4-Bromophenyl)cyclopropanol

Similarity: 0.90

Chemical Structure| 100760-04-1

A218595 [100760-04-1]

(S)-1-(4-Bromophenyl)ethanol

Similarity: 0.90

Bromides

Chemical Structure| 30951-66-7

A185319 [30951-66-7]

2-(3-Bromophenyl)propan-2-ol

Similarity: 0.98

Chemical Structure| 2077-19-2

A512869 [2077-19-2]

2-(4-Bromophenyl)propan-2-ol

Similarity: 0.95

Chemical Structure| 134615-22-8

A265000 [134615-22-8]

(S)-1-(3-Bromophenyl)ethanol

Similarity: 0.93

Chemical Structure| 109240-30-4

A505333 [109240-30-4]

1-(4-Bromophenyl)cyclopropanol

Similarity: 0.90

Chemical Structure| 100760-04-1

A218595 [100760-04-1]

(S)-1-(4-Bromophenyl)ethanol

Similarity: 0.90

Alcohols

Chemical Structure| 30951-66-7

A185319 [30951-66-7]

2-(3-Bromophenyl)propan-2-ol

Similarity: 0.98

Chemical Structure| 2077-19-2

A512869 [2077-19-2]

2-(4-Bromophenyl)propan-2-ol

Similarity: 0.95

Chemical Structure| 134615-22-8

A265000 [134615-22-8]

(S)-1-(3-Bromophenyl)ethanol

Similarity: 0.93

Chemical Structure| 109240-30-4

A505333 [109240-30-4]

1-(4-Bromophenyl)cyclopropanol

Similarity: 0.90

Chemical Structure| 100760-04-1

A218595 [100760-04-1]

(S)-1-(4-Bromophenyl)ethanol

Similarity: 0.90